{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:23:47Z","timestamp":1778261027776,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    Therapeutic plasma exchange (TPE) may enhance the elimination of drugs from human plasma. Removal of apixaban during TPE has not been extensively described previously.\n                    <jats:bold>Case:<\/jats:bold>\n                    This is a retrospective report of a 76-year-old man admitted to the hospital on apixaban with acute worsening of respiratory and bulbar symptoms due to myasthenia gravis. On hospital day (HOD) 1, TPE was initiated for management of myasthenic crisis. Apixaban levels were obtained before and after a TPE session on HOD 3. On HOD 3, the patient\u2019s apixaban plasma level decreased from 88 ng\/mL before TPE to 81 ng\/mL after. Apixaban displayed an elimination half-life of 65.5 hours with intervening TPE.\n                    <jats:bold>Discussion\/conclusions:<\/jats:bold>\n                    We report no clinically significant apixaban removal in a patient undergoing TPE for myasthenic crisis. This differs from previous reports. Supplemental dosing or rescheduling of apixaban doses around TPE sessions may be unnecessary, though more data are needed.\n                  <\/jats:p>","DOI":"10.1177\/87551225251369344","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:11:26Z","timestamp":1757419886000},"page":"48-51","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of Therapeutic Plasma Exchange on Apixaban Plasma Levels"],"prefix":"10.1177","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2122-492X","authenticated-orcid":false,"given":"David","family":"Hensler","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Michigan Medicine, Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Burghardt","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Michigan Medicine, Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13159"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.11.1529"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.10.017"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-020-00989-1"},{"key":"e_1_3_2_6_2","article-title":"Prescribing information","author":"Eliquis (apixaban)","year":"2012","unstructured":"Eliquis (apixaban). Prescribing information. Bristol-Myers Squibb Company; 2012.","journal-title":"Bristol-Myers Squibb Company;"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/87551225231207273"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.14503\/THIJ-14-4424"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-151835"},{"issue":"7","key":"e_1_3_2_10_2","first-page":"159","article-title":"Management of apixaban anticoagulation in a patient requiring therapeutic plasma exchange: a case report and a literature review","volume":"79","author":"Pilkov\u00e1 A","year":"2024","unstructured":"Pilkov\u00e1 A, Hartinger JM, Mal\u00edkov\u00e1 I, et al Management of apixaban anticoagulation in a patient requiring therapeutic plasma exchange: a case report and a literature review. Pharmazie. 2024;79(7):159-162.","journal-title":"Pharmazie"},{"key":"e_1_3_2_11_2","volume-title":"Clinical Pharmacokinetics","author":"Murphy J","year":"2012","unstructured":"Murphy J. Clinical Pharmacokinetics. 5th ed. American Society of Health-System Pharmacists; 2012.","edition":"5"}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225251369344","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225251369344","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225251369344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:33:31Z","timestamp":1777602811000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225251369344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/87551225251369344"],"URL":"https:\/\/doi.org\/10.1177\/87551225251369344","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]}}}